Stephen B H Kent Net Worth

The estimated Net Worth of Stephen B H Kent is at least 56.3 千$ dollars as of 22 October 2010. Stephen Kent owns over 8,000 units of Enzo Biochem stock worth over 10,716$ and over the last 17 years Stephen sold ENZ stock worth over 45,575$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Stephen Kent ENZ stock SEC Form 4 insiders trading

Stephen has made over 2 trades of the Enzo Biochem stock since 2010, according to the Form 4 filled with the SEC. Most recently Stephen sold 8,000 units of ENZ stock worth 34,400$ on 22 October 2010.

The largest trade Stephen's ever made was selling 8,000 units of Enzo Biochem stock on 22 October 2010 worth over 34,400$. On average, Stephen trades about 1,050 units every 8 days since 2008. As of 22 October 2010 Stephen still owns at least 9,654 units of Enzo Biochem stock.

You can see the complete history of Stephen Kent stock trades at the bottom of the page.

What's Stephen Kent's mailing address?

Stephen's mailing address filed with the SEC is C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK CITY, NY, 10022.

Insiders trading at Enzo Biochem

Over the last 22 years, insiders at Enzo Biochem have traded over 2,615,763$ worth of Enzo Biochem stock and bought 1,070,494 units worth 3,103,461$ . The most active insiders traders include Bradley Louis Radoff、Management Corp Harbert Dis...、Elazar Rabbani. On average, Enzo Biochem executives and independent directors trade stock every 127 days with the average trade being worth of 59,099$. The most recent stock trade was executed by Kara Cannon on 21 February 2024, trading 10,640 units of ENZ stock currently worth 11,810$.

What does Enzo Biochem do?

enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.

Complete history of Stephen Kent stock trades at Enzo Biochem

Enzo Biochem executives and stock owners

Enzo Biochem executives and other stock owners filed with the SEC include:

• Elazar Rabbani,
  Chairman of the Board, Chief Executive Officer, Secretary
• Barry Weiner,
  President, Treasurer
• Dr. Elazar Rabbani Ph.D.,
  Co-Founder, Chairman, Chief Scientific Officer & Sec.
• Barry W. Weiner,
  Founder, Treasurer & Pres
• Dieter Schapfel,
  Chief Medical Director - Enzo Clinical Labs
• Kara Cannon,
  Chief Commercial Officer
• Dr. Dieter Schapfel M.D.,
  Chief Medical Director of Enzo Clinical Labs
• David Bench,
  Chief Financial Officer, Principal Accounting Officer
• David A. Bench,
  CFO & Principal Accounting Officer
• Dov Perlysky,
  Lead Independent Director
• Rebecca Fischer,
  Independent Director
• Ian Walters,
  Independent Director
• Mary Tagliaferri,
  Independent Director
• Kara Cannon,
  Chief Commercial Officer
• Hamid Erfanian,
  CEO & Director
• Bruce A. Dey,
  VP of Sales & Marketing - Enzo Clinical Labs
• Gregory M. Bortz,
  Director
• Bernard L Kasten,
  Director
• David C Goldberg,
  VP CorpDev Pres Enz Clin Labs
• Steven J Pully,
  Director
• Bruce A. Hanna,
  Director
• James Michael O'brien,
  EVP of Finance
• Peter J Iv Clemens,
  10% owner
• Management Corp Harbert Dis...,
  
• Stanford S Warshawsky,
  Director
• Fabian Blank,
  Director
• Christine Fischette,
  Pres., Enzo Therapeutics, Inc.
• Irwin Gerson,
  Director
• John Delucca,
  Director
• Stephen B H Kent,
  Director
• Dean Engelhardt,
  Executive Vice President
• Melvin F Lazar,
  Director
• Barbara E Thalenfeld,
  VP Corporate Development
• John B Sias,
  Director
• Carl W Balezentis,
  Pres., Enzo Life Sciences
• Kevin Krenitsky,
  President, Enzo Clinical Labs
• Shahram K Rabbani,
  COO, Treasurer & Secretary
• Norman E Kelker,
  Senior Vice President
• Herbert B Bass,
  VP of Finance
• Andrew P Whiteley,
  VP BusDev-COO Enzo Lif Sci Inc
• Bradley Louis Radoff,
  Director
• James G. Wolf,
  
• Hamid Erfanian,
  Chief Executive Officer
• Patricia Eckert,
  Chief Financial Officer